Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research

Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation

May 21, 2019 —  San Francisco, CA —  Verily, an Alphabet company, announced a strategic alliance with Otsuka and other pharmaceutical companies to develop digitally innovative, patient-centered clinical research programs using Project Baseline's evidence generation platform and tools. The Baseline Platform is designed to engage more patients and clinicians in research, increase the speed and ease of conducting studies and collect more comprehensive, higher quality data, including outside the four walls of a clinic. “Evidence generation through research is the backbone of improving health outcomes. We need to be inclusive and encourage diversity in research to truly understand health and disease, and to provide meaningful insights about new medicines, medical devices and digital health solutions,” said Jessica Mega, M.D., chief medical and scientific officer, Verily. “Novartis, Otsuka, Pfizer and Sanofi have been early adopters of advanced technology and digital tools to improve clinical research operations, and together we’re taking another step towards making research accessible and generating evidence to inform better treatments and care.” Click here to read the full release issued by Verily.  Please note that if you click the link, you will be directed to another website.